Trenbolone Acetate is officially classified as a veterinarian grade anabolic androgenic steroid. The Trenbolone hormone itself was first created in the late 1960’s and the Acetate version would be sold under the names Finajet and Finaject. However, this is not the only Trenbolone compound. The same hormone would appear on the pharmaceutical market under the name Parabolan and was manufactured by Negma Laboratories out of France. This version of Trenbolone was comprised of the same active hormone that makes up Finajet and Finaject with the ester attached being the only exception. Parabolan carries the much larger Hexahydrobenzylcarbonate ester. It would also be the only Tren hormone ever manufactured for human use and would be discontinued in 1997 despite a lot of therapeutic success. See the Parabolan profile for more information.
Trenbolone is a potent androgen that is primarily used in cattle, so there is even less information at our disposal on this compound or its effects on the female endocrine system than any other drug. It is the one drug that seems to produce results as significant as the side effects that are associated with it. Women are generally advised to stay clear of Trenbolone considering the strong androgenic component which eradicates any possibility of running Trenbolone without sides. The more seasoned female athlete will run it in the off season in order to reap the muscle building benefits of the drug whilst maintaining a relatively low body fat. On the other hand running it during contest preparation will preserve the newly added muscle mass while on a calorie restricted diet. The less daring athlete will run Trenbolone during the last few weeks of contest preparation or even limit their use to the week before the show - with a more frequent injection schedule.